AU2008272721B2 - Modified globin proteins with altered electron transport pathway - Google Patents

Modified globin proteins with altered electron transport pathway Download PDF

Info

Publication number
AU2008272721B2
AU2008272721B2 AU2008272721A AU2008272721A AU2008272721B2 AU 2008272721 B2 AU2008272721 B2 AU 2008272721B2 AU 2008272721 A AU2008272721 A AU 2008272721A AU 2008272721 A AU2008272721 A AU 2008272721A AU 2008272721 B2 AU2008272721 B2 AU 2008272721B2
Authority
AU
Australia
Prior art keywords
protein
leu
haemoglobin
composition
reductant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008272721A
Other languages
English (en)
Other versions
AU2008272721A1 (en
Inventor
Christopher Eric Cooper
Brandon Jon Reeder
Michael Thomas Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Essex Enterprises Ltd
Original Assignee
University of Essex Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Essex Enterprises Ltd filed Critical University of Essex Enterprises Ltd
Publication of AU2008272721A1 publication Critical patent/AU2008272721A1/en
Assigned to THE UNIVERSITY OF ESSEX ENTERPRISES LIMITED reassignment THE UNIVERSITY OF ESSEX ENTERPRISES LIMITED Alteration of Name(s) of Applicant(s) under S113 Assignors: WIVENHOE TECHNOLOGY LIMITED
Application granted granted Critical
Publication of AU2008272721B2 publication Critical patent/AU2008272721B2/en
Assigned to UNIVERSITY OF ESSEX ENTERPRISES LIMITED reassignment UNIVERSITY OF ESSEX ENTERPRISES LIMITED Alteration of Name(s) of Applicant(s) under S113 Assignors: THE UNIVERSITY OF ESSEX ENTERPRISES LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2008272721A 2007-06-29 2008-06-26 Modified globin proteins with altered electron transport pathway Active AU2008272721B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0712685.7A GB0712685D0 (en) 2007-06-29 2007-06-29 Improvements relating to oxygen-carrying proteins (2)
GB0712685.7 2007-06-29
PCT/GB2008/002199 WO2009004309A1 (en) 2007-06-29 2008-06-26 Modified globin proteins with altered electron transport pathway

Publications (2)

Publication Number Publication Date
AU2008272721A1 AU2008272721A1 (en) 2009-01-08
AU2008272721B2 true AU2008272721B2 (en) 2013-06-27

Family

ID=38420974

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008272721A Active AU2008272721B2 (en) 2007-06-29 2008-06-26 Modified globin proteins with altered electron transport pathway

Country Status (9)

Country Link
US (1) US8609814B2 (enExample)
EP (1) EP2170948B1 (enExample)
JP (1) JP2010531659A (enExample)
CN (1) CN101711255A (enExample)
AU (1) AU2008272721B2 (enExample)
BR (1) BRPI0812403B8 (enExample)
CA (1) CA2690370A1 (enExample)
GB (1) GB0712685D0 (enExample)
WO (1) WO2009004309A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2858495A4 (en) 2012-04-30 2016-06-01 Dow Agrosciences Llc VEHICLES FOR RELEASING PESTICIDE COMPOSITIONS
GB201704006D0 (en) * 2017-03-13 2017-04-26 Univ Essex Modified globin proteins
JP7387597B2 (ja) 2017-07-18 2023-11-28 ヴァーテック・バイオ・インコーポレイテッド ヘモグロビンを含む代用血液及び作製方法
GB201721503D0 (en) * 2017-12-20 2018-01-31 Univ Essex Modified globin proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8711614D0 (en) * 1987-05-16 1987-06-24 Medical Res Council Proteins
US5884323A (en) * 1995-10-13 1999-03-16 3Com Corporation Extendible method and apparatus for synchronizing files on two different computer systems
EP0859789A1 (en) 1995-10-23 1998-08-26 Rice University Hemoglobin mutants that reduce heme loss
GB0712683D0 (en) 2007-06-29 2007-08-08 Wivenhoe Technology Ltd Improvements relating to oxygen-carrying proteins(1)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Baudin V et al, Transfusion Clinique et Biologique, 1995, 2(6):463-467 *
Baudin-Creuza V et al, Journal of Biological Chemistry, 1999, 274(36):25550-25554 *
Griffon N et al, Protein Science, 1998, 7(3):673-680 *
Vasseur-Godbillon C et al, The FEBS Journal, 2006, 273(1):230-241 *

Also Published As

Publication number Publication date
EP2170948A1 (en) 2010-04-07
WO2009004309A1 (en) 2009-01-08
CA2690370A1 (en) 2009-01-08
AU2008272721A1 (en) 2009-01-08
US8609814B2 (en) 2013-12-17
BRPI0812403A2 (pt) 2014-12-02
GB0712685D0 (en) 2007-08-08
JP2010531659A (ja) 2010-09-30
BRPI0812403B8 (pt) 2021-05-25
CN101711255A (zh) 2010-05-19
BRPI0812403B1 (pt) 2019-08-27
EP2170948B1 (en) 2016-11-02
US20100137189A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
US11124559B2 (en) Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
AU2008272721B2 (en) Modified globin proteins with altered electron transport pathway
AU2017232073B2 (en) Methods for preparing PEG-hemoglobin conjugates using reduced reactant ratios
US12180266B2 (en) Modified haemoglobin proteins
US5349054A (en) Activated benzenepentacarboxylate-crosslinked low oxygen affinity hemoglobin
US6974794B1 (en) Hemoglobin-antioxidant conjugates
WO2009004310A1 (en) Modified globin proteins with attenuated electron transport pathway
US5334705A (en) Benzenetricarboxylate derivative-crosslinked low oxygen affinity hemoglobin
US6204009B1 (en) Nucleic acids encoding mutant recombinant hemoglobins containing heme pocket mutations
Apperson Globin engineering studies: optimizing the designs of circularly permuted myoglobin and single-chain hemoglobin
HK1177255A (en) Methods for preparing peg-hemoglobin conjugates using reduced reactant ratios

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)